Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2/PHASE3
166 participants
INTERVENTIONAL
2001-07-31
2007-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atrasentan
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject is currently active in an atrasentan clinical study OR has histologically or cytologically documented diagnosis of prostate adenocarcinoma and is considered hormone refractory;
* Karnofsky Performance Score greater than or equal to 60;
* Adequate hematologic function and liver function tests;
* No New York Heart Association (NYHA) class greater than or equal to 2.
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Abbott
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gary Gordon, MD
Role: STUDY_DIRECTOR
Abbott
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Prostate Oncology Specialists
Marina del Rey, California, United States
Western Clinical Research, Inc.
Torrance, California, United States
South Florida Medical Research
Aventura, Florida, United States
Beth Isreal Medical Center, Phillips Ambulatory Care Ceneter
New York, New York, United States
ViaHealth Rochester General Hospital Center for Urology
Rochester, New York, United States
Oregon Urology Specialist, Division of Clinical Research
Springfield, Oregon, United States
University of Pittsburgh Department of Urology
Pittsburgh, Pennsylvania, United States
Cross Cancer Institute
Edmonton, Alberta, Canada
CroMedia Prime/Prime Trials Vancouver Hospital
Vancouver, British Columbia, Canada
Ken Janz MD
Burlington, Ontario, Canada
McMaster Institute of Urology
Hamilton, Ontario, Canada
McGill University Health Center Royal VIctoria Hosptial
Montreal, Quebec, Canada
Hoptial de Ranguell Service d'Urologie
Toulouse, Cedex, France
University Hospital Rotterdam, Department of Urology
Rotterdam, , Netherlands
Leighton Hospital Urology Research Dept., Michael Heal Outpatients Dept.
Crewe, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
M01-304
Identifier Type: -
Identifier Source: org_study_id